Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology

Clinical Lymphoma and Myeloma

Volumn 7, Issue 8, 2007, Pages 518-523

  Jagannath, Sundar ^a  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Amyloidosis; Light chain deposition disease; MGUS; Oligosecretory myeloma; Plasma cytoma

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; MELPHALAN;

AMYLOIDOSIS; ARTICLE; AUTOMATION; CHEMOSENSITIVITY; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG MEGADOSE; ELECTROPHORESIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MEASUREMENT; MONITORING; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; PLASMA CELL; PLASMA CELL DYSCRASIA; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TECHNOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 35748965000     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.036     Document Type: Article

References (31)

1. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783.
2. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48:1437-1444.
3. Abadie JM, Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a veterans affairs population. Ann Clin Lab Sci 2006; 36:157-162.
4. Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002; 48:655-657.
5. Hill PG, Forsyth JM, Rai B, et al. Serum free light chains: an alternative test to urine Bence Jones proteins when screening for monoclonal gammopathies. Clin Chem 2006; 52:1743-1748.
6. Abraham RS, Katzmann JA, Clark RJ, et al. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119:274-278.
7. Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361:489-491.
8. Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108:1979-1983.
9. Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97:2900-2902.
10. Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51:878-881.
11. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122:78-84.
12. Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126:348-54.
13. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106:812-817.
14. Tate JR, Mollee P, Dimeski G, et al. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007; 376:30-36.
15. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467-1473.
16. Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81:1575-1578.
17. Bakshi NA, Gulbranson R, Garstka D, et al. Serum free light chain (FLC) measurement can aid capillary zone electriphoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol 2005; 124:214-218.
18. Nowrousian MR, Brandhorst D, Sammet C, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11:8706-8714.
19. Snyder MR, Katzmann JA, Abraham RS, et al. Elimination of the need for urine studies during diagnostic work up of monoclonal gammopathies by using serum immunofixation and free light chain assays. Presented at: the 19th Annual Meeting of the Association of Medical Laboratory Immunologists; August 23-26, 2006; Washington, DC.
20. Hassoun H, Reich L, Klimek VM, et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006; 132:155-161.
21. Van Gysel M, Marien G, Verhoef G, et al. Free light chain testing in follow-up of multiple myeloma. Clin Chem Lab Med 2006; 44:1044-1046.
22. Pratt G, Mead GP, Godfrey KR, et al. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma 2006; 47:21-28.
23. Mösbauer U, Ayuk F, Schieder H, et al. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica 2007; 92:275-276.
24. Mehta J, Stein R, Vickrey E, et al. The relationship between serum free light chain assay and serum immunofixation electrophoresis. Haematologica 2007; 92:203-204.
25. Kumar S, Rajkumar SV, Plevak M, et al. Comparison of serum free light chain levels and 24 hour urinary monoclonal protein secretion in patients with myeloma: concordant changes with response to therapy. Blood 2006; 108:355b (Abstract #5064).
26. Singhal S, Stein R, Vickrey E, et al. The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007; 109:3611-3612.
27. Dispenzieri A, Zhang L, Snyder M, et al. FLC as a marker of response in a mature dataset: ECOG E9486. Haematologica 2007; 92:204.
28. Alyanakian MA, Abbas A, Delarue R, et al. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol 2004; 75:246-248.
29. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92:143-144.
30. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107:3378-3383.
31. Cavallo F, Rasmussen E, Zangari M, et al. Serum free-lire chain (sFLC) assay in multiple myeloma (MM): clinical correlates and prognostic implications in newly diagnosed MM patients treated with total therapy 2 or 3 (TT2/3). Blood 2005; 106:974a (Abstract #3490).